{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:15:52Z","timestamp":1788736552341,"version":"build-2803163510"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1097\/md.0000000000004631","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T15:51:53Z","timestamp":1472140313000},"page":"e4631","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence and risk factors for efavirenz-based antiretroviral treatment\u2013associated severe vitamin D deficiency"],"prefix":"10.1097","volume":"95","author":[{"given":"Hanna","family":"Nyl\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiy","family":"Habtewold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getnet","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Diczfalusy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-38-20210226","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/17476348.2015.1042458","article-title":"Vitamin D supplementation: a comprehensive review on supplementation for tuberculosis prophylaxis","volume":"9","author":"Turnbull","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"R2-38-20210226","doi-asserted-by":"crossref","first-page":"e40036","DOI":"10.1371\/journal.pone.0040036","article-title":"Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy","volume":"7","author":"Sudfeld","year":"2012","journal-title":"PLoS One"},{"key":"R3-38-20210226","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1570162X13666150608102030","article-title":"Vitamin D deficiency may be associated with a more rapid decline in CD4 cell count to <350\u200acells\/microL in untreated HIV-infected adults","volume":"13","author":"Klassen","year":"2015","journal-title":"Curr HIV Res"},{"key":"R4-38-20210226","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jn\/135.2.310","article-title":"Vitamin D intake: a global perspective of current status","volume":"135","author":"Calvo","year":"2005","journal-title":"J Nutr"},{"key":"R5-38-20210226","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e31821ae418","article-title":"Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States","volume":"57","author":"Adeyemi","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-38-20210226","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3851\/IMP1502","article-title":"Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D","volume":"15","author":"Brown","year":"2010","journal-title":"Antivir Ther"},{"key":"R7-38-20210226","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1545109711399657","article-title":"Vitamin D deficiency in HIV-infected women on antiretroviral therapy living in the tropics","volume":"10","author":"Conrado","year":"2011","journal-title":"J Int Assoc Physicians AIDS Care (Chic"},{"key":"R8-38-20210226","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/QAD.0b013e32834544af","article-title":"Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?","volume":"25","author":"Fux","year":"2011","journal-title":"AIDS"},{"key":"R9-38-20210226","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clnu.2012.05.022","article-title":"Vitamin D status in young HIV infected women of various ethnic origins: incidence of vitamin D deficiency and possible impact on bone density","volume":"32","author":"Shahar","year":"2013","journal-title":"Clin Nutr"},{"key":"R10-38-20210226","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/tpj.2012.46","article-title":"Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients","volume":"13","author":"Habtewold","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R11-38-20210226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1741-7015-11-253","article-title":"Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review","volume":"11","author":"Lawn","year":"2013","journal-title":"BMC Med"},{"key":"R12-38-20210226","doi-asserted-by":"crossref","first-page":"e27810","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"key":"R13-38-20210226","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-13-261","article-title":"Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study","volume":"13","author":"Mukonzo","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R14-38-20210226","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/0091270004269142","article-title":"Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital","volume":"44","author":"Hariparsad","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R15-38-20210226","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/clpt.2011.129","article-title":"Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis","volume":"90","author":"Ngaimisi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R16-38-20210226","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1124\/mol.51.5.741","article-title":"Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3","volume":"51","author":"Schmiedlin-Ren","year":"1997","journal-title":"Mol Pharmacol"},{"key":"R17-38-20210226","doi-asserted-by":"crossref","first-page":"25125","DOI":"10.1074\/jbc.M201323200","article-title":"Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes","volume":"277","author":"Drocourt","year":"2002","journal-title":"J Biol Chem"},{"key":"R18-38-20210226","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/mol.111.076356","article-title":"An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway","volume":"81","author":"Wang","year":"2012","journal-title":"Mol Pharmacol"},{"key":"R19-38-20210226","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsbmb.2012.09.012","article-title":"Interplay between vitamin D and the drug metabolizing enzyme CYP3A4","volume":"136","author":"Wang","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R20-38-20210226","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/jac\/dkr304","article-title":"Long-term effect of efavirenz autoinduction on plasma\/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients","volume":"66","author":"Habtewold","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R21-38-20210226","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/clpt.2010.172","article-title":"Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients","volume":"88","author":"Ngaimisi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R22-38-20210226","first-page":"484","article-title":"Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4beta-hydroxycholesterol during efavirenz treatment and efavirenz\/rifampicin co-treatment","volume":"13","author":"Ngaimisi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R23-38-20210226","doi-asserted-by":"crossref","first-page":"e86919","DOI":"10.1371\/journal.pone.0086919","article-title":"Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes","volume":"9","author":"Mukonzo","year":"2014","journal-title":"PLoS One"},{"key":"R24-38-20210226","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2217\/pgs.14.73","article-title":"CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure","volume":"15","author":"Mukonzo","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R25-38-20210226","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0b013e32833c3281","article-title":"Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase","volume":"24","author":"Welz","year":"2010","journal-title":"AIDS"},{"key":"R26-38-20210226","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2217\/pgs.15.35","article-title":"Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study","volume":"16","author":"Habtewold","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R27-38-20210226","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-38-20210226","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bcpt.12230","article-title":"Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives","volume":"115","author":"Nylen","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R29-38-20210226","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/AAC.00283-10","article-title":"No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment","volume":"54","author":"Burhenne","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-38-20210226","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12020-015-0548-3","article-title":"Seasonal variations in serum 25-hydroxy vitamin D levels in a Swedish cohort","volume":"49","author":"Klingberg","year":"2015","journal-title":"Endocrine"},{"key":"R31-38-20210226","first-page":"63","article-title":"The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency","volume":"121","author":"Bolland","year":"2008","journal-title":"N Z Med J"},{"key":"R32-38-20210226","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ajcn\/60.4.619","article-title":"McCollum Award Lecture, 1994: vitamin D\u2013new horizons for the 21st century","volume":"60","author":"Holick","year":"1994","journal-title":"Am J Clin Nutr"},{"key":"R33-38-20210226","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajcn\/86.5.1376","article-title":"Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls","volume":"86","author":"Wejse","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"R34-38-20210226","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/156482651303400408","article-title":"Vitamin D insufficiency in a sunshine-sufficient area: southern Ethiopia","volume":"34","author":"Gebreegziabher","year":"2013","journal-title":"Food Nutr Bull"},{"key":"R35-38-20210226","doi-asserted-by":"crossref","first-page":"e0120963","DOI":"10.1371\/journal.pone.0120963","article-title":"Vitamin D deficiency and its predictors in a country with thirteen months of sunshine: the case of school children in central Ethiopia","volume":"10","author":"Wakayo","year":"2015","journal-title":"PLoS One"},{"key":"R36-38-20210226","doi-asserted-by":"crossref","first-page":"e112858","DOI":"10.1371\/journal.pone.0112858","article-title":"Micronutrient deficiencies and related factors in school-aged children in Ethiopia: a cross-sectional study in Libo Kemkem and Fogera districts, Amhara Regional State","volume":"9","author":"Herrador","year":"2014","journal-title":"PLoS One"},{"key":"R37-38-20210226","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clnu.2013.04.018","article-title":"Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients","volume":"33","author":"Theodorou","year":"2014","journal-title":"Clin Nutr"},{"key":"R38-38-20210226","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s12879-014-0652-7","article-title":"Vitamin D and tuberculosis: a multicenter study in children","volume":"14","author":"Venturini","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R39-38-20210226","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.5588\/ijtld.11.0146","article-title":"Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis","volume":"16","author":"Conesa-Botella","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R40-38-20210226","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/infdis\/jis693","article-title":"Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy","volume":"207","author":"Sudfeld","year":"2013","journal-title":"J Infect Dis"},{"key":"R41-38-20210226","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00042560-200111010-00004","article-title":"Surrogate markers for disease progression in treated HIV infection","volume":"28","author":"Ghani","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-38-20210226","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/QAD.0b013e328347f6f7","article-title":"Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study","volume":"25","author":"Viard","year":"2011","journal-title":"AIDS"},{"key":"R43-38-20210226","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5588\/ijtld.14.0348","article-title":"Vitamin D status and incidence of tuberculosis among contacts of pulmonary tuberculosis patients","volume":"19","author":"Arnedo-Pena","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"R44-38-20210226","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.bcp.2008.02.030","article-title":"Retinoids induce cytochrome P450 3A4 through RXR\/VDR-mediated pathway","volume":"75","author":"Wang","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"R45-38-20210226","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/infdis\/jiu259","article-title":"25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings","volume":"210","author":"Havers","year":"2014","journal-title":"J Infect Dis"},{"key":"R47-38-20210226","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jiac.2015.07.003","article-title":"Increase of 25-hydroxyvitamin D levels after initiation of combination antiretroviral therapy","volume":"21","author":"Koga","year":"2015","journal-title":"J Infect Chemother"},{"key":"R48-38-20210226","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12937-015-0072-6","article-title":"Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy","volume":"14","author":"Coelho","year":"2015","journal-title":"Nutr J"},{"key":"R49-38-20210226","doi-asserted-by":"crossref","first-page":"e0117123","DOI":"10.1371\/journal.pone.0117123","article-title":"Vitamin D (3)supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial","volume":"10","author":"Steenhoff","year":"2015","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:31:50Z","timestamp":1620959510000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201608230-00038"}},"subtitle":["A prospective cohort study"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":48,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004631","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}